MA50942A - Protéines de liaison à l'adn modifiées - Google Patents
Protéines de liaison à l'adn modifiéesInfo
- Publication number
- MA50942A MA50942A MA050942A MA50942A MA50942A MA 50942 A MA50942 A MA 50942A MA 050942 A MA050942 A MA 050942A MA 50942 A MA50942 A MA 50942A MA 50942 A MA50942 A MA 50942A
- Authority
- MA
- Morocco
- Prior art keywords
- binding proteins
- dna binding
- modified dna
- modified
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762593824P | 2017-12-01 | 2017-12-01 | |
US201762610014P | 2017-12-22 | 2017-12-22 | |
US201862618966P | 2018-01-18 | 2018-01-18 | |
US201862641806P | 2018-03-12 | 2018-03-12 | |
US201862646198P | 2018-03-21 | 2018-03-21 | |
US201862664814P | 2018-04-30 | 2018-04-30 | |
US201862664817P | 2018-04-30 | 2018-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50942A true MA50942A (fr) | 2020-10-07 |
Family
ID=66664596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050942A MA50942A (fr) | 2017-12-01 | 2018-11-30 | Protéines de liaison à l'adn modifiées |
Country Status (15)
Country | Link |
---|---|
US (1) | US20200397917A1 (fr) |
EP (1) | EP3717505A4 (fr) |
JP (3) | JP7401432B2 (fr) |
KR (1) | KR20200107949A (fr) |
CN (1) | CN111727259B (fr) |
AU (2) | AU2018375192B2 (fr) |
BR (1) | BR112020010883A2 (fr) |
CA (1) | CA3083765A1 (fr) |
CL (1) | CL2020001451A1 (fr) |
IL (1) | IL274926A (fr) |
MA (1) | MA50942A (fr) |
MX (1) | MX2020005561A (fr) |
SG (1) | SG11202004926WA (fr) |
TW (2) | TW202319538A (fr) |
WO (1) | WO2019109051A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017060731A1 (fr) | 2015-10-09 | 2017-04-13 | University Of Southampton | Modulation de l'expression génique et criblage de l'expression de protéines dérégulée |
EP3933041B1 (fr) | 2015-12-14 | 2024-01-31 | Cold Spring Harbor Laboratory | Oligomères antisens destinés au traitement du retard mental autosomique dominante |
KR20240024326A (ko) * | 2017-05-19 | 2024-02-23 | 엔코디드 테라퓨틱스, 인크. | 고활성 조절 요소 |
PL3673080T3 (pl) | 2017-08-25 | 2024-03-11 | Stoke Therapeutics, Inc. | Oligomery antysensowne do leczenia stanów i chorób |
WO2019204766A1 (fr) | 2018-04-19 | 2019-10-24 | The Regents Of The University Of California | Compositions et méthodes pour l'édition génique |
CA3141900C (fr) * | 2019-05-29 | 2023-06-06 | Encoded Therapeutics, Inc. | Compositions et procedes de regulation selective de genes |
EP4041894A1 (fr) * | 2019-09-23 | 2022-08-17 | Omega Therapeutics, Inc. | COMPOSITIONS ET PROCÉDÉS DE MODULATION DE L'EXPRESSION GÉNIQUE DU FACTEUR NUCLÉAIRE HÉPATOCYTAIRE 4-ALPHA (HNF4a) |
GB201913974D0 (en) * | 2019-09-27 | 2019-11-13 | King S College London | Vector |
WO2021141041A1 (fr) * | 2020-01-07 | 2021-07-15 | 大日本住友製薬株式会社 | Agent thérapeutique pour tauopathies |
KR20230022409A (ko) | 2020-05-11 | 2023-02-15 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머 |
JP2023526267A (ja) * | 2020-05-13 | 2023-06-21 | エフ. ホフマン-ラ ロシュ アーゲー | プログラニュリン標的オリゴヌクレオチドアゴニスト |
WO2022125420A1 (fr) * | 2020-12-09 | 2022-06-16 | City Of Hope | Composés et procédés de traitement de fibrose kystique |
CN115074389A (zh) * | 2022-06-13 | 2022-09-20 | 华南农业大学 | 稳定表达鸭坦布苏病毒ns1蛋白的细胞系的构建方法及其应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030104526A1 (en) * | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US7329728B1 (en) * | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
CA2435394C (fr) * | 2001-01-22 | 2018-01-09 | Sangamo Biosciences, Inc. | Proteines de liaison en doigt de gant modifiees |
DE60233555D1 (de) * | 2001-02-21 | 2009-10-15 | Novartis Ag | Die nukleotidsequenz ann bindende zink-finger domänen |
EP1481087A4 (fr) * | 2002-02-07 | 2005-12-21 | Scripps Research Inst | Bibliotheques en doigt de gant |
WO2009060316A2 (fr) * | 2007-09-14 | 2009-05-14 | The Governors Of The University Of Alberta | Polypeptides se liant au virus de l'hépatite b et leurs procédés d'utilisation |
EA029151B1 (ru) * | 2011-09-06 | 2018-02-28 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ |
EP3494997B1 (fr) * | 2012-07-25 | 2019-09-18 | The Broad Institute, Inc. | Protéines de liaison à l'adn inductibles, outils de perturbation du génome et leurs applications |
AR095982A1 (es) * | 2013-04-03 | 2015-11-25 | Aliophtha Ag | Factores de transcripción artificiales modificados genéticamente para superar el atrapamiento endosómico |
AR095984A1 (es) * | 2013-04-03 | 2015-11-25 | Aliophtha Ag | Factores artificiales de transcripción que regulan receptores nucleares y su uso terapéutico |
US10076574B2 (en) * | 2013-10-25 | 2018-09-18 | Wayne State University | Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming |
WO2015153760A2 (fr) * | 2014-04-01 | 2015-10-08 | Sangamo Biosciences, Inc. | Procédés et compositions destinés à la prévention ou au traitement d'un trouble du système nerveux |
WO2017048466A1 (fr) * | 2015-09-15 | 2017-03-23 | The Regents Of The University Of California | Compositions et procédés pour l'administration d'agents biothérapeutiques |
EP3933041B1 (fr) * | 2015-12-14 | 2024-01-31 | Cold Spring Harbor Laboratory | Oligomères antisens destinés au traitement du retard mental autosomique dominante |
AU2017227803B2 (en) * | 2016-03-02 | 2024-05-02 | Defne AMADO | Therapy for frontotemporal dementia |
US20190127713A1 (en) * | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
-
2018
- 2018-11-30 CN CN201880088375.4A patent/CN111727259B/zh active Active
- 2018-11-30 AU AU2018375192A patent/AU2018375192B2/en active Active
- 2018-11-30 MA MA050942A patent/MA50942A/fr unknown
- 2018-11-30 SG SG11202004926WA patent/SG11202004926WA/en unknown
- 2018-11-30 BR BR112020010883-9A patent/BR112020010883A2/pt unknown
- 2018-11-30 EP EP18884285.0A patent/EP3717505A4/fr active Pending
- 2018-11-30 MX MX2020005561A patent/MX2020005561A/es unknown
- 2018-11-30 KR KR1020207018993A patent/KR20200107949A/ko not_active Application Discontinuation
- 2018-11-30 JP JP2020529582A patent/JP7401432B2/ja active Active
- 2018-11-30 WO PCT/US2018/063498 patent/WO2019109051A1/fr active Application Filing
- 2018-11-30 CA CA3083765A patent/CA3083765A1/fr active Pending
- 2018-12-03 TW TW111138440A patent/TW202319538A/zh unknown
- 2018-12-03 TW TW107143330A patent/TWI835761B/zh active
-
2020
- 2020-05-25 IL IL274926A patent/IL274926A/en unknown
- 2020-05-28 US US16/886,129 patent/US20200397917A1/en active Pending
- 2020-05-29 CL CL2020001451A patent/CL2020001451A1/es unknown
-
2022
- 2022-09-14 JP JP2022145839A patent/JP2022171792A/ja active Pending
-
2023
- 2023-12-20 AU AU2023285810A patent/AU2023285810A1/en active Pending
-
2024
- 2024-03-19 JP JP2024043454A patent/JP2024069591A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021505133A (ja) | 2021-02-18 |
US20200397917A1 (en) | 2020-12-24 |
CN111727259A (zh) | 2020-09-29 |
KR20200107949A (ko) | 2020-09-16 |
JP2022171792A (ja) | 2022-11-11 |
TW201925474A (zh) | 2019-07-01 |
EP3717505A1 (fr) | 2020-10-07 |
AU2018375192B2 (en) | 2023-11-09 |
AU2023285810A1 (en) | 2024-01-18 |
WO2019109051A1 (fr) | 2019-06-06 |
IL274926A (en) | 2020-07-30 |
JP2024069591A (ja) | 2024-05-21 |
CA3083765A1 (fr) | 2019-06-06 |
CN111727259B (zh) | 2024-04-19 |
MX2020005561A (es) | 2020-10-12 |
BR112020010883A2 (pt) | 2020-11-10 |
JP7401432B2 (ja) | 2023-12-19 |
TW202319538A (zh) | 2023-05-16 |
CL2020001451A1 (es) | 2020-11-06 |
EP3717505A4 (fr) | 2021-12-01 |
TWI835761B (zh) | 2024-03-21 |
AU2018375192A1 (en) | 2020-07-02 |
SG11202004926WA (en) | 2020-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50942A (fr) | Protéines de liaison à l'adn modifiées | |
MA54513A (fr) | Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs | |
MA50613A (fr) | Molécules de liaison spécifique à l'hpv | |
MA41414A (fr) | Protéines de liaison agonistes d' icos | |
MA52709A (fr) | Administration d'adn | |
IL272064A (en) | Binding proteins 1 | |
MA41313A (fr) | Anticorps de liaison de la protéine april modifiés | |
MA43576A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
MA51113A (fr) | Édition de gène à l'aide d'un adn modifié à extrémités fermées (adnce) | |
MA43816A (fr) | Protéines de liaison inductibles et méthodes d'utilisation | |
KR102349259B9 (ko) | 친화성 시약을 이용한 핵산 시퀀싱 | |
MA50100A (fr) | Adn à extrémité fermée (cedna) modifié | |
MA44670A (fr) | Protéines de liaison trispécifiques et/ou trivalentes | |
MA42808A (fr) | Anticorps de liaison à l'il-8 et leurs utilisations | |
MA52273A (fr) | Protéines de liaison à un antigène anti-trem2 et leurs utilisations | |
MA50746A (fr) | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive | |
MA55347A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
MA53616A (fr) | Protéines bispécifiques modifiées | |
MA42821A (fr) | Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci | |
EP3613771A4 (fr) | Molécule de liaison spécifique à protéine lrig-1 et son utilisation | |
DK3275895T3 (da) | Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf | |
MA50255A (fr) | Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1) | |
MA51619A (fr) | Inhibiteurs de la protéine kinase dépendante de l'adn | |
MA42613A (fr) | Filtration en profondeur chargée de protéines de liaison à un antigène | |
GB201802338D0 (en) | Antigen binding proteins |